Myriad Genetics Inc (NASDAQ:MYGN)
| 21.20 Delayed Data As of May 18 |  -1.45 / -6.40%Today’s Change | 18.98 Today|||52-Week Range 36.95 | -23.19% Year-to-Date |
Latest MYGN News | Press Releases
| Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down May 06 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 22.65 |
| Today’s open | 22.11 |
| Day’s range | 21.01 - 22.60 |
| Volume | 802,800 |
| Average volume (3 months) | 548,876 |
| Market cap | $1.8B |
Data as of 4:01pm ET, 05/18/2022
Growth & Valuation
| Earnings growth (last year) | +87.01% |
| Earnings growth (this year) | -1,050.00% |
| Earnings growth (next 5 years) | +6.00% |
| Revenue growth (last year) | +8.14% |
| P/E ratio | NM |
| Price/Sales | 3.12 |
| Price/Book | 1.85 |
Competitors
Data as of 4:27pm ET, 05/18/2022
Financials
| Next reporting date | August 2, 2022 |
| EPS forecast (this quarter) | $0.03 |
| Annual revenue (last year) | $690.6M |
| Annual profit (last year) | -$27.2M |
| Net profit margin | -3.94% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Salt Lake City, Utah |
Forecasts
